Our easy-to-read patient fact sheet compares and contrasts sinus arrhythmia vs AFib (atrial fibrillation) symptoms.

like atrial fibrillation. Other types of heart disease include coronary artery disease, heart valve disease, and heart failure. An electrocardiogram, also called an ECG or EKG, is a diagnostic tool ...

NEW HAVEN, Conn. (WTNH) — In Friday’s Health headlines, February is heart month, and we’re talking about AFib, portable EKG devices, and how stress this season can be hard on the heart.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 ...

That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than makes up for the $295 million that Boston Scientific put down to ...

Although percentages differed in ischemic cardiomyopathy and prior history of Afib, the differences between the two groups were not statistically significant. Among the 90 patients with LVSD in ...

Those can include an electrocardiogram (EKG or ECG), a noninvasive test that records the heart’s electrical activity. If someone has AFib, simply feeling for a pulse can strongly suggest its presence ...

Yang et al. propose a new approach to identify features associated with the risk of atrial fibrillation (AF) using standard 12-lead raw electrocardiogram (ECG) tracing. The features identified in ...

Catheter ablation is one of the most effective rhythm-control strategies for atrial fibrillation (AF). Conventional catheter ablation is performed using thermo-energy sources via either radiofrequency ...

Milestone Pharmaceuticals Inc. announced that the PDUFA date for its nasal spray CARDAMYST™ (etripamil) for treating Paroxysmal Supraventricular Tachycardia (PSVT) has been set for March 27, 2025.

Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a trial of etripamil nasal spray in patients with AFib-RVR in the at-home setting.

Phase 3 pivotal trial in AFib-RVR expected to begin enrollment in H1 2025. Milestone plans to initiate a trial of etripamil nasal spray in patients with AFib-RVR in the at-home setting. The protocol ...